| Dr Michael A Rubin, MD | |
|
4500 Sunny Isle Ste 9, Christiansted, VI 00820 | |
| (340) 778-1802 | |
| (340) 778-6460 |
| Full Name | Dr Michael A Rubin |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 51 Years |
| Location | 4500 Sunny Isle Ste 9, Christiansted, Virgin Island |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427050285 | NPI | - | NPPES |
| 4099597 | Other | TN | BCBS |
| 3337923 | Medicaid | TN |
| Facility Name | Location | Facility Type |
|---|---|---|
| Gov Juan F Luis Hospital & Medical Ctr | St croix, VI | Hospital |
| Entity Name | The Rubin Heart Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639426802 PECOS PAC ID: 8325299795 Enrollment ID: O20121112000386 |
News Archive
Concord Medical Services Holdings Limited, the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced higher revenues, net income, and earnings per ADS for its unaudited consolidated financial results for the second quarter ended June 30, 2011 compared with the second quarter ended June 30, 2010.
Britain's top paediatricians and childhood vaccination experts have come out in force to condemn how the public has been misled over the measles, mumps and rubella (MMR) vaccine.
A team of investigators at the University of Kentucky has made a thought-provoking discovery about a type of cholesterol previously believed to be a "bad guy" in the development of heart disease and other conditions.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO was first approved in January 2012 for people with CF ages 6 and older who have at least one copy of the G551D mutation.
Research from the Stowers Institute provides evidence suggesting that cancer cells might streamline their genomes in order to proliferate more easily.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael A Rubin, MD 8989 Forest Hill Irene Cv, Germantown, TN 38139-6619 Ph: (901) 517-4048 | Dr Michael A Rubin, MD 4500 Sunny Isle Ste 9, Christiansted, VI 00820 Ph: (340) 778-1802 |
News Archive
Concord Medical Services Holdings Limited, the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced higher revenues, net income, and earnings per ADS for its unaudited consolidated financial results for the second quarter ended June 30, 2011 compared with the second quarter ended June 30, 2010.
Britain's top paediatricians and childhood vaccination experts have come out in force to condemn how the public has been misled over the measles, mumps and rubella (MMR) vaccine.
A team of investigators at the University of Kentucky has made a thought-provoking discovery about a type of cholesterol previously believed to be a "bad guy" in the development of heart disease and other conditions.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO was first approved in January 2012 for people with CF ages 6 and older who have at least one copy of the G551D mutation.
Research from the Stowers Institute provides evidence suggesting that cancer cells might streamline their genomes in order to proliferate more easily.
› Verified 8 days ago
Angel Anthony Lake, MD Cardiovascular Disease Medicare: May Accept Medicare Assignments Practice Location: 4007 Diamond Ruby, Christiansted, VI 00820 Phone: 340-778-6311 | |
Carmen Beatrice Cintron, DO Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2024 Estate Mount Welcome, Ste 10, Christiansted, VI 00820 Phone: 340-227-7233 Fax: 757-483-9578 | |
Kirana Kefalos, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 3227 Estate Golden Rock, Suite #4, Christiansted, VI 00820 Phone: 340-718-9700 Fax: 340-718-5300 | |
Michelle Dizon, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 4500 Sion Farm Suite 3b, Christiansted, VI 00820 Phone: 340-778-5780 Fax: 888-686-4557 | |
Dante P Galiber, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 4500 Sunny Isle, The Heart Center, Pc, Christiansted, VI 00820 Phone: 340-778-1802 Fax: 340-778-6460 | |
Ramesh Billy Lakhram, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 4007 Estate Diamond Ruby, Christiansted, VI 00820 Phone: 340-778-6311 |